Related Experiment Videos
Clinical evaluation of a DTaP-HepB-IPV combined vaccine
Insights
The combined diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV) is safe and effective in infants. This single injection provides immunogenicity comparable to separate vaccines, offering a convenient immunization alternative.
Area of Science:
- Pediatric Vaccinology
- Immunology
- Public Health
Background:
- Infant immunization requires multiple injections, posing challenges for adherence.
- A combined DTaP-HepB-IPV vaccine offers a potential solution for simplifying pediatric vaccination schedules.
Purpose of the Study:
- To evaluate the prelicensure clinical data of a novel DTaP-HepB-IPV combined vaccine.
- To assess the safety and immunogenicity of this multi-component pediatric vaccine.
Main Methods:
- Clinical trials involving over 7,000 infants receiving a 3-dose primary series of DTaP-HepB-IPV.
- Safety assessment through monitoring solicited and unsolicited adverse events.
- Immunogenicity evaluation by measuring seroprotection/vaccine response rates for each component.
Main Results:
- The DTaP-HepB-IPV vaccine demonstrated a favorable safety profile, with no significant serious adverse events reported.
- Adverse reaction rates were comparable to separate vaccine administration.
- Immunogenicity was similar to individual vaccine components, indicating robust immune responses.
Conclusions:
- The DTaP-HepB-IPV combined vaccine is safe and immunogenic in infants following a 3-dose primary series.
- This single-injection vaccine presents a safe and effective alternative to multiple-injection regimens, potentially improving vaccination compliance.
Objective:
To provide an overview of prelicensure clinical data for a new pediatric vaccine that combines diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccines into a single injection (DTaP-HepB-IPV combined vaccine; Pediarix, GlaxoSmithKline Biologicals, Rixensart, Belgium).
Methods:
The safety and immunogenicity of DTaP-HepB-IPV combined vaccine have been evaluated extensively in clinical trials in infants. To date, DTaP-HepB-IPV combined vaccine has been administered to more than 7,000 infants as a 3-dose primary series during the first year of life.
Results:
Studies show that DTaP-HepB-IPV combined vaccine is generally safe, well tolerated, and has not caused any significant serious adverse events. The rates of solicited and unsolicited reports of adverse reactions following vaccination were similar between groups receiving DTaP-HepB-IPV combined vaccine and comparator groups receiving the vaccine components separately. DTaP-HepB-IPV combined vaccine induces immunogenicity (as measured by seroprotection or vaccine response rates to each of the vaccine components [diphtheria, tetanus, 3 pertussis antigens, hepatitis B, and poliovirus types 1, 2, and 31) similar to licensed vaccine components administered separately.
Conclusion:
In prelicensure clinical studies, DTaP-HepB-IPV combined vaccine was safe and immunogenic when given to infants as a primary 3-dose series. As a single injection of multiple vaccine components, DTaP-HepB-IPV combined vaccine may provide a safe and effective alternative to the current multiple-injection immunization regimen.